AnaptysBio (ANAB) vs Alpha Tau Medical (DRTS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Alpha Tau Medical (DRTS) has outperformed AnaptysBio (ANAB) over the past year, gaining 245.0% versus a gain of 129.2%. Over five years, ANAB leads with a +138.8% price change compared with +44.1% for DRTS. AnaptysBio is the larger company by market cap ($1.35 billion vs $1.27 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANAB | DRTS |
|---|---|---|
| Share price | $45.15 | $13.70 |
| Market cap | $1.35B | $1.27B |
| 1-day change | -1.10% | -3.86% |
| YTD return | +41.24% | +187.88% |
| 1-year return | +129.24% | +245.04% |
| 5-year return | +138.84% | +44.08% |
| Forward P/E | 8.91 | — |
| EPS (TTM) | $-0.96 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $72.36 | $15.79 |
| 52-week low | $20.18 | $3.43 |
| Distance from 52-week high | -37.60% | -13.23% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +93.24% | +29.92% |
| Average volume | 563.32K | 566.95K |
| Shares outstanding | 29.90M | 92.48M |
| Employees | — | 121 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DRTS has outperformed ANAB by 115.8 percentage points over the past year.
About AnaptysBio
ANAB stock →AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations
About Alpha Tau Medical
DRTS stock →Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors.
Health Care · Medical/Dental Instruments · 121 employees
ANAB vs DRTS FAQ
Which is bigger, AnaptysBio or Alpha Tau Medical?
AnaptysBio (ANAB) is larger, with a market capitalization of $1.35B compared with $1.27B for Alpha Tau Medical (DRTS).
Which stock has performed better over the past year, ANAB or DRTS?
DRTS returned +245.04% over the past 12 months, compared with +129.24% for ANAB (price return, excluding dividends). Past performance does not predict future results.
Are AnaptysBio and Alpha Tau Medical in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for AnaptysBio and Medical/Dental Instruments for Alpha Tau Medical.